SCHEMBL23330484

SCHEMBL23330484

O=C(Nc1cnc(Cl)nc1Cl)N1CCOCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.50
▸ KDM4E B2RXH2 3/20 0.49
▸ HSD17B10 Q99714 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ TSHR P16473 1/20 0.49
▸ POLB P06746 1/20 0.48
▸ SMN1; SMN2 Q16637 6/20 0.47
▸ NPC1 O15118 3/20 0.47
▸ RAB9A P51151 3/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ ABCC1 P33527 1/20 0.45
▸ GAA P10253 3/20 0.44
▸ HPGD P15428 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ AKR1C3 P42330 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ ESR2 Q92731 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23330486 0.84 MAPT (0.46) MAPTKDM4EHSD17B10ALDH1A1TSHR
SCHEMBL23330530 0.80 ALDH1A1 (0.54) MAPTKDM4EALDH1A1TSHRPOLB
SCHEMBL21114791 0.78 MAPT (0.60) MAPTKDM4EHSD17B10ALDH1A1TSHR
SCHEMBL23330688 0.77 MEN1 (0.49) MAPTHSD17B10TSHRPOLBSMN1; SMN2
SCHEMBL23331087 0.75 HDAC1 (0.47) KMT2A
SCHEMBL23330489 0.72 MAPT (0.44) MAPTKDM4EHSD17B10ALDH1A1TSHR
SCHEMBL17111799 0.72 NFKB1 (0.40) —
SCHEMBL23331258 0.71 PTK2 (0.43) KDM4EHSD17B10ALDH1A1POLBHPGD
SCHEMBL24978426 0.70 HSD17B10 (0.51) KDM4EHSD17B10ALDH1A1TSHRSMN1; SMN2
SCHEMBL24978673 0.70 PIP5K1C (0.41) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230028221-A1 EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) 2023-01-26 — — US disclosed
WO-2021083380-A1 EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海科技大学 2021-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230028221-A1 EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF CYP4F11, CYP4A11, HSD11B1 MAPT 113/4885KDM4E 2018/4885HSD17B10 332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback